Inhibition of T lymphocyte proliferation

Inhibition of T lymphocyte proliferation is a functional outcome wherein drugs, peptides, immune cells (e.g., regulatory T cells), or metabolic enzymes (e.g., IDO) suppress the ability of T lymphocytes (a subset of white blood cells) to enter the cell cycle and divide in response to immune stimulation[1][2][3][4]. This process is a mechanism underlying many immunosuppressive therapies and is relevant in transplantation, treatment of autoimmune disease, and tumor immune evasion. The underlying molecular mechanisms leading to this effect are diverse and may include disruption of cytokine signaling (especially IL-2), catabolism of cellular metabolites (e.g., tryptophan depletion via IDO), signaling modulation (e.g., through cAMP and adenosine), or direct drug-mediated blockade of T cell receptor-linked pathways[1][2][3]. This designation should not be used as a canonical target in databases, and for structured data, it is more appropriate to map this to specific molecular targets (such as “Interleukin-2 receptor”, “Calcineurin”, “Indoleamine 2,3-dioxygenase”, etc.) depending on context and mechanism.

Calcineurin inhibition (e.g., cyclosporin A, tacrolimus); mTOR pathway inhibition (e.g., sirolimus); Inhibition of interleukin-2 (IL-2) production or response; Tryptophan catabolism by indoleamine 2,3-dioxygenase (IDO); Modulation of cyclic AMP and adenosine signaling (via Tregs); Inhibition by certain fatty acids (mechanism varies and may be independent of eicosanoids).